drugset
drugset / Trial / NCT03734913

A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors

NCT03734913 ↗

Phase 1 Unknown 65 enrolled Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1602 in participants with basal cell carcinoma, adenocarcinoma of esophagogastric junction, small cell lung cancer, neuroendocrine neoplasm and other advanced solid tumors.

Timeline

Start
2019-01-25
Primary completion
2021-07-31
Completion
2021-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ZSP1602 Unknown — Oral

Indications

gastroesophageal junction adenocarcinoma glioblastoma medulloblastoma skin basal cell carcinoma small cell lung carcinoma